Exelixis Inc. is a biopharmaceutical company focused on developing and commercializing small-molecule therapies for cancer treatment. Established in 1994, Exelixis has carved a niche in oncology by de... Exelixis Inc. is a biopharmaceutical company focused on developing and commercializing small-molecule therapies for cancer treatment. Established in 1994, Exelixis has carved a niche in oncology by delivering highly targeted medicinal solutions. One of its cornerstone products, Cabometyx, is utilized in treating advanced renal cell carcinoma and hepatocellular carcinoma, significantly impacting the healthcare sector's approach to managing these cancers. Additionally, the company is engaged in a robust pipeline of projects aimed at diversifying its oncological therapeutic offerings. Exelixis' collaborations with other leading pharmaceutical entities enhance its research capabilities and extend its reach globally, reinforcing its role in the biopharmaceutical landscape. By focusing on unmet medical needs within the oncology sector, Exelixis plays a critical role in influencing both patient care and future therapeutic developments in cancer treatment.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

Exelixis is not subject to EU Taxonomy reporting

Based on current regulatory requirements, Exelixis is not required to report EU Taxonomy data under the CSRD framework. As a result, we have not conducted a detailed EU Taxonomy data review for this company.

If you believe this assessment should be revisited, you may submit a data coverage request and our team will review the company's regulatory applicability.

Would you like us to review Exelixis's data?

Create a free Tracenable account to signal interest in having our team review data for Exelixis.

Legal Center Contact Us